Premium
Decreased hepatic drug demethylation in patients receiving chemo‐immunotherapy
Author(s) -
Lipton Allan,
Hepner Gershon W.,
White Deborah S.,
Harvey Harold A.
Publication year - 1978
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(197805)41:5<1680::aid-cncr2820410506>3.0.co;2-r
Subject(s) - medicine , cyclophosphamide , immunotherapy , chemotherapy , drug , chemoimmunotherapy , gastroenterology , demethylation , pharmacology , cancer , biochemistry , gene expression , chemistry , dna methylation , gene
The effect of immunotherapy and chemotherapy on hepatic N‐demethylation of aminopyrine was studied by means of the aminopyrine breath test (ABT) in 32 patients with cancer. The aminopyrine breath test (ABT) was decreased in 3 of 11 patients (27.3%) receiving intradermal BCG (± DTIC) at a dose of 3 × 10 7 viable organisms. One of 4 (25%) patients receiving intradermal BCG (± DTIC) at 3 × 10 8 viable organisms per dose developed an altered ABT. Changes were not seen in patients receiving aerosol BCG (2 patients), intravenous C. parvum (2 patients), subcutaneous C. parvum (3 patients), and intravenous Cyclophosphamide (2 patients). Six of 7 patients (85.7%) receiving both intravenous C. parvum and Cyclophosphamide had a decreased ABT. These data indicate that chemo‐immunotherapy depressed hepatic aminopyrine N‐demethylation and suggests that patients treated with chemoimmunotherapy should be carefully observed for possible alterations of hepatic drug metabolism.